English

Biohit's Financial Reporting and Annual General Meeting in 2013

Report this content

 

Biohit will release its financial statements for 2012 on Wednesday 27nd of February 2013 at 9:30 AM.

Biohit Oyj’s Annual General Meeting has been planned for Monday 8th of April 2013 at 3:00 PM in Helsinki, Finland. The Board of Directors will call the General Meeting at a later date.

Company will publish three interim reports in 2013, based on the following schedule:

  • Interim report for period January - March 2013 (Q1) on Thursday 25th of April 2013 at 9:30 AM.
  • Interim report for period January - June 2013 (Q2) on Thursday 8th August 2013 at 9:30 AM.
  • Interim report for period January - September 2013 (Q3) on Thursday 24th October 2013 at 9:30 AM.

The published economic reports and other stock exchange releases will be available on Biohit's website at www.biohithealthcare.com/investors. The website also contains an online form for ordering electronic copies, which will be e-mailed to you.

 

For further details:

CEO Semi Korpela
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com

 

 

Biohit Oyj is a Finnish biotechnology company operating globally that was established in 1988. Biohit’s mission is “Innovating for Health” and “Cancer Prevention”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to responsibility and it is our duty to innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located China and UK. Since 1999, Biohit’s Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.

 

 

Subscribe